Loading data for BOLD — first visit, this takes a few seconds.
Boundless Bio Inc. (BOLD)
NasdaqGS: BOLD
· Real-Time Price · USD
2.96
-0.04 (-1.33%)
At close: Aug 27, 2026, 3:19 PM
The price, the headline numbers and the latest news, in one place.
Boundless Bio Inc. (BOLD) Stock Price, Analysis & Data
-1.33% (1D)
No data available
| Bid | 2.09 |
| Market Cap | 66.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.01M |
| 0.38 | |
| -2.85 | |
| n/a | |
| -2.97 | |
| P/B (ttm) | 0.99 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 3.75 |
| Volume | 118,475 |
| Avg. Volume (20D) | 1,274,982 |
| Open | 3.16 |
| Previous Close | 3.00 |
| Day's Range | 2.90 - 3.16 |
| 52-Week Range | 0.96 - 3.16 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2024
Employees 28
Stock Exchange NasdaqGS
Ticker Symbol BOLD
Website https://boundlessbio.com
Financial Performance
In 2025, Boundless Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -58.2M, a decrease of -10.96%.
Financial StatementsEarnings Surprise
Boundless Bio has released their quarterly earnings on Aug 7, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.06 misses estimates by -0.48, with -51.43% YoY decline.
Page 1 of 2